Department of Hematology

Hadassah University Hospital

Ein-Karem, Jerusalem

Prof. Deborah Rund was born in New York in 1949.

After completing a Master’s Degree in Social Work at the Wurzweiler School of Social Work of the Yeshiva University, she went on to study medicine at Columbia University College of Physicians and Surgeons (1976-1980).

She completed her residency in Internal Medicine at Columbia Presbyterian Hospital in New York, and following Board Certification in 1983, she remained at Columbia Presbyterian, where she completed a combined Hematology-Oncology Fellowship (1983-6).

After a year of research at Columbia University Health Science Center’s Genetics Department, Prof. Rund and her family made Aliyah and she immediately joined the hematology staff at Hadassah University Hospital. She rapidly rose on the academic ladder and now holds the rank of Associate Professor.

Prof. Rund is extensively involved in teaching.  She received awards for excellence in teaching medical students. In addition, she is extensively involved in patient care. 

She also has her own research laboratory, concentrating on three major areas of research interest, which also are intimately tied to her clinical interests.

She also participates in several key committees in the hospital and in the medical school. She is reviewing many publications and is an Associate Editor of The British Journal of Hematology.

List of Publications

Original articles

1. Lindenbaum, J., Tse-Eng, D., Butler, V.P. and Rund, D.G. Urinary excretion of reduced metabolites of digoxin. Am. J. Med., 71:67-74, 1981.

2. Lindenbaum, J., Rund, D. G., Butler, V.P., Tse-Eng, D. and Saha, J.R. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N. Engl, J. Med., 305:789-794, 1981.

3. Butler, V.P., Tse-Eng, D., Lindenbaum, J., Kalman, S.M., Preibisz, J.J., Rund, D.G. and Wissel, P.S. the development and application of a radioimmunoassay for dihydrodigoxin, a digoxin metabolite. J. Pharmacol. Ther., 221:123-131, 1982.

4. Rund, D.G., Lindenbaum, J., Dobkin, J. F., Butler, V. P. and Saha, J.R. Decreased digoxin cardioinactive-reduced metabolites after administration as an encapsulated liquid concentrate. Clin. Pharmacol. Exp. Ther., 34: 738-743, 1983.

5. Rund, D.G., Dobkin, C. and Bank, A. Regulated expression of amplified human beta-globin genes. Blood 70:733-739,1987.

6. Bank, A., Donovan-Peluso, M., Lerner, N. and Rund, D. Human globin gene expression after gene transfer. Blood Cells 13:269-275, 1987.

7. Rund, D., Kornhendler, N., Shalev, O., Oppenheim, A. The origin of sickle cell alleles in Israel. Human Genetics, 85:521-524,     1990.

8.Oppenheim, A., Rund, D., Yaari, A., Miller, B.A., Kazazian, H.H. Jr., Nathan, D.G., and Rachmilewitz, E.A. Intrinsic capacity for high fetal hemoglobin production in a Druze patient with thalassemia intermedia is due to an unlinked genetic determinant. Human Genetics, 86:175-180, 1990.

9. Rund, D., Filon, D., Granat, M., Hemo, Y., Cohen, T., Oppenheim, A., Rachmilewitz, E.A. Prenatal diagnosis of thalassemia: Identification of mutations in conjunction with gene amplification in vitro. Harefuah (in Hebrew), J. Israel Med. Assoc., 120:57-60, 1991

10. Rund, D., Cohen, T., Filon, D., Dowling, C.E., Warren, T., Barak, I.,     Rachmilewitz, E.A., Kazazian, H.H. Jr., Oppenheim, A. Evolution of    a genetic disease in an ethnic isolate:  -thalassemia in the Jews of Kurdistan.b Proc. Natl. Acad. Sci. USA., 88:310-314, 1991.

 11. Rund, D., Filon, D., Strauss, N., Rachmilewitz, E.A., Oppenheim, A. Mean corpuscular volume (MCV) of heterozygotes varies with severity of the mutation. Blood, 79:238-243, 1992.        

12. Rund, D., Filon, D., Warren, T.C., Dowling, C.E., Kazazian, H.H. Jr., Rachmilewitz, E.A. and Oppenheim, A. -thalassemia in Israeli ethnic groups and its applicationbMolecular analysis of  to prenatal diagnosis. Hematology Reviews and Communications, 6: 117-124, 1992.

13. Rund, D., Dowling, C., Rachmilewitz, -globinbE.A., Kazazian, H.H. Jr., Oppenheim, A. Novel mutations in the  polyadenylylation signal reveal extended transcripts and new RNA polyadenylylation sites. Proc. Natl. Acad. Sci. USA., 89: 4324-4328, 1992.

14. Rund, D., Abramov, A., Oppenheim, A., -globinb-thalassemia due to a severe mutation in the bFilon, D. Silent carrier  gene. Eur. J. Ped., 152:574-576, 1993.

15. Oppenheim, A., Jury, C.L., Rund, D., Vuilliamy, T.J., Luzzatto, L. G6PD Mediterranean accounts for the high prevalence of G6PD in Kurdish Jews. Human Genetics, 91:293-294, 1993.

16. Oppenheim, A., Oron, V., Filon, D., Fearson, C.C., Kazazian, H.H. Jr., Rund, D. Sporadic alleles, including a -thalassemia in Ashkenazi Jews.bnovel mutation, characterize  Human Mutation, 2:155-157, 1993.

17. Filon, D., Oron,V., Krichevski S., Shaag, A., Warren, T.C., Goldfarb, A., Shneor, Y., Koren, A., Aker, M., Abramov, A., Rachmilewitz, E.A., Rund, D.-globin mutations inb, Kazazian, H.H. Jr., and Oppenheim, A. Diversity of  Israeli ethnic groups reflects recent   historic events. Am. J. Hum. Genet, 54: 836-843, 1994.

18. Oron, V., Filon, D., Oppenheim, A. and Rund, D. Severe thalassemia -globin triplication withaintermedia caused by interaction of homozygosity for  bheterozygosity for o-thalassemia. Br. J. Haematology, 86: 377-379, 1994.

19. Rund, D., Rachmilewitz, E.A. Thalassemia 1995: Older patients, new therapies. Blood Reviews, 9: 25-32, 1995.

20. Filon, D., Oron, V., Shawa, R., Elborno, E., Najjar, K., Tulchinsky, T., Rachmilewitz, E.A., Rund, D., Oppenheim, A. Spectrum of -thalassemia mutations in the Gaza area.b Human Mutation,  5:351-353, 1995.

21. Rund, D., Rachmilewitz, E.A. Advances in the pathophysiology and treatment of thalassemia. Critical Reviews in Hematology-Oncology, 20:237-254, 1995.

22. Gillis, S., Dann E.J., Rund, D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. American J. Hematol, 51:26-31, 1995.

23. Filon, D., Oron, V., Schneor, Y., Rund, D., Oppenheim, A. A new -globin gene discovered during prenatalbframeshift mutation in codon 10 of the  diagnosis. Human Mutation, 6:278-279, 1995.

24. Oppenheim, A., Filon, D., Faerman, M., Oron, V., Smith, P., Rund-thalassemiab, D. The evolution of  since early human history.  Cellular Pharmacology, 3:195-198, 1996.

25. Ben-Yehuda, D., Krichevsky, S., Caspi, O., Rund, D., Polliack, A., Abeliovitch, Zelig, O., Paltiel, O., Or, R., Peretz, T., Ben-Neriah, S., Yehuda, O., Rachmilewitz, E. p53 mutations and microsatellite instability in therapy-related leukemia suggests mutator phenotype. Blood, 88:4296-4303,1996.

26. Oron-Karni, V., Filon, D., Rund, D., Oppenheim, A. A novel mechanism generating short deletions/insertions following slippage is suggested 2-globin gene.aby a mutation in the human  Human Molecular Genetics, 6:881-885, 1997.

27. Fridlender, Z., Rund, D. Multidrug resistance (MDR1): its significance in hematological malignancies and its role in normal tissues and blood cells. Harefuah (in Hebrew) 133:64-70, 1997.

28. Rund, D, Schaap, T., Gillis, S. Intensive plasmapheresis for thrombotic thrombocytopenic purpura: long term outcome. J. of  Clinical Apheresis, 12:194-195, 1997.

29. Rund, D., Oron-Karni, O., Filon, D., -thalassemiabGoldfarb, A., Rachmilewitz, E., Oppenheim, A. Genetic analysis of  intermedia in Israel: Diversity of mechanism and unpredictability of phenotype. Am. J. Hematol, 54:16-23, 1997.

30. Rund, D., Dagan, M. Dalyot, N., Kimchi-Sarfaty, C., Schoenlein, P.,     Gottesman, MM, Oppenheim, A. SV40 pseudovirions efficiently transduce human hematopoietic cells with multidrug resistance (MDR1) gene. Human Gene Therapy, 9:649-657, 1998.

31. Rund, D., Fibach, E., Goldfarb, A., Friedberg, A., Rachmilewitz, E.  Heme -thalassemia: in vitro and in vivo effects.barginate therapy for  Acta Hematologica, 100:82-84, 1998.

32. Oron-Karni, V., Filon, D., Oppenheim, A., Rund, D. Rapid -globin deletions/rearrangements usingadetection of the common Mediterranean  PCR. Am J. Hematol, 58:306-310,1998.

33. Steiner, H., Polliack, A., Kimchi-Sarfaty, C., Libster, D., Fibach, E., Rund, D. Differences in rhodamine 123 efflux in B type chronic lymphatic leukemia suggest possible gender and stage variations in drug resistance gene activity. Annals of Hematol, 76:189-194,1998.

34. Rund, D., Azar, I., Shperling, O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv. Exp. Med. Biol. 1999;457:71-5.

35. Dalyot-Hermann, N., Rund, D., Oppenheim, A. Expression of -thalassemia patients using anb-globin in primary erythroid progenitors of b SV40-based gene delivery system. J. Hematotherapy, 8:593-599, 2000.

36. Rund, D., Rachmilewitz, E. A. New -thalassemia.btrends in the treatment of  Crit. Rev. Hematol. Oncol. 33:105-118, 2000.

37. Oron-Karni, V., Filon, D., Shifrin, Y., Fried, E., Pogrebijsky, G., Oppenheim, A., Rund, D-globina. Diversity of  -thalassemia in Israel.amutations and clinical presentation of  Am J. Hematol. 65: 196-203, 2000.

38. Rund, D., Rachmilewitz, E.A. Pathophysiology -thalassemia; treatment implications.b- and aof  Sem. Hematol., 38:343-349, 2001.

39. Mahmoud Abd El-latif, M., Filon, D., Rund, D., Oppenheim, A., Kanaan, M. The -globin mutation IVS1-6 accounts for half of the thalassemia chromosomes in theb Palestinian population of the mountain region. Hemoglobin, 26:33-40, 2002.

40. Kimchi-Sarfaty, C., Ben-Nun-Shaul, O., Rund, D., Pastan, I., Oppenheim, A., Gottesman, M.M. In vitro packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum. Gene Ther., 13:299-310, 2002.

41.  Durst, R.,  Rund, D., Schurr, D., 1, Eliav, O., Ben-Yehuda, D., Shpizen, S., Ben-Avi, L., Schaap, T., Pelz, F., Leiterdorf, E. One year's experience with an LDL apheresis system. Isr. Med. Assoc. Journal, 4:677-680, 2002.

42. Altarescu, G., Rudensky, B., Abrahamov, A., Goldfarb, A., Rund, D., Goldfarb, A. Zimran, A., Elstein, D. Plasma chitotriosidase activity in -thalassemia.bpatients with  Am. J. Hematol. 71:7-10, 2002.

43. Mittleman, M., Zeidman, A., Kanter, P., Katz, O., Oster, H., Rund, D., Neumann, D. Erythropoietin has an anti-myeloma effect: a hypothesis based on a clinical observation supported by animal            studies. Eur J Haematol, 72:155-65, 2004.

44. Rund, D and Ben-Yehuda, D.  Therapy-related leukemia and myelodysplasia: Evolving concepts of pathogenesis and treatment. Hematology, in press, 2004.

45. Ulitsky, J., Mosheiff, R., Gimon, Z., Muggia-Sulam, M., Rund, D. Post-traumatic reactive thrombocytosis is frequent and varies according to injury site and severity. Submitted, Injury.

Case Reports

1. Dann, E.J., Gillis, S., Polliack, A., Okon, E., Rund, D. Rachmilewitz, E. A. Fatal tumor lysis following 2-chlorodeoxyadenosine in a patient with refractory chronic lymphocytic leukemia. New Engl. J. Med., 329:1547-1548, 1993.

2. Ben Hur,T., Rund, D., Agmon, Y., Steiner, I. Hypereosinophilia presenting as recurrent, benign mononeuritis multiplex. Isr. J. Med. Sci,. 30:709-711, 1994.

3. Varadi, G., Or, R., Rund, D., Orbach, H., Slavin, S., Nagler, A. Severe polyarthritis following in vivo CAMPATH-1G. Bone Marrow Transplantation, 16:843-845, 1995.

4. Oron-Karni, V. Filon, D., Rund, D., Oppenheim, A. Prenatal - anadiagnosis based on simultaneous DNA analysis of -globin genes.bd  American J. Hematol., 53:203-204, 1996 (letter).

5. Rund, D., Ben Neriah, S, Yehuda, O., Okon, E., Polliack, A. De novo acute myeloid leukemia with near-pentaploidy: diploid karyotype and lymphoblastic phenotype at relapse. Leuk. Lymphoma, 25:585-591, 1997.

6. Da'as, N., Lossos, I., Yahalom, V., Rund, D., Wolf, D. G., Zelig, O., Ben Yehuda, D. Candida abscess in a patient with acute Lymphoblastic leukemia. Eur J. Med. Res, 2:365-366, 1997.

7. Gofrit, O., Rund, D., Shapiro, A., Pappo, O., Landau, E.H., Pode, D. Segmental testicular infarction due to sickle cell disease. J. Urology, 160:835-6, 1998.

8. Shapira, M., Hirshberg, B., Amir, G., Rund, D. 6;9 translocation in myelodysplastic syndrome. Cancer Genet Cytogenet. 112:57-9, 2000.

9. Cohen, Y., Amir, G., Da'as, N., Gillis, S., Rund, D. Polliack, A. Acute myocardial infarction as the presenting feature of acute myelpblastic leukemia with extreme hyperleukocytosis. Am. J. Hematol. 71:47-49, 2002.

10. Antopolsky, M., Kleinman, Y., Rund, D., Da'as, N. Metfromin induced hemolytic anemia in a patient with glucose-6-phosphate dehydrogenase deficiency. Diabetes Care 26:956-7, 2003.

11. Abdelrahman, N., Kleinman, Y., Rund, D., Da'as, N. Hyponatremia associated with the initiation of reboxetine therapy. Eur. J. Clin. Pharm. 5:457, Published online May, 2003.

12. Cohen, Y., Rund, D., Moualem, E., Kalish, Y., Polliack, A. Carbemazepine-induced generalized "pseudolymphoma"-like syndrome. Israel Med. Assoc. J. 5:457-458, 2003.

13. Fridlender, Z., Rund, D. Myocardial infarction in a beta-thalassemia patient: first report. Am. J. Hematol., 75: 52-55, 2004.

Patent

1. Ariella Oppenheim, Nava Dalyot, Deborah Rund, Orly Ben-Nun-Shaul, Ziv Sandalon, Tova Chajek-Shaul and Shulamit Metzger. SV40-derived DNA constructs comprising exogenous DNA sequences. US Patent #6,090,608, 18.7.2000.

Chapters in Books

1. Lindenbaum, J., Rund, D.G., Butler, V.P. and Saha, J.R. Clinical implications of the conversion of digoxin to reduced metabolities. in Ambrosioni, E. and Carbonin, P.U. (Eds.): Bioavailability and Metabolism of Cardiac Glycosides. Geneva, Switzerland: Bioscience Ediprint, 1981.

2. Bank, A., Donovan-Peluso, M., LaFlamme, S., Rund, D. and Lerner, -thalassemia. Birth Defects: Original ArticlebN. Approaches to gene therapy for  Series: Thalassemia: Pathophysiology and Management, Vol. 22. New York: March of Dimes Birth Defects Foundation, 1986.

3. Bank, A., Donovan-Peluso, M., LaFlamme, S., Rund, D. and Lerner, -thalassemia. Birth Defects: OriginalbN. Approaches to gene therapy for  Articles series, Thalassemia: Pathophysiology and Management, Vol. 23: 339-346, 1988.

4. Rund, D., Filon, D., Dowling, C., Kazazian, H.H. Jr., Rachmilewitz, E.A. and Oppenheim, A. molecular studies of -thalassemia inb Israel: Mutational analysis and expression studies. Annals of the N.Y. Acad. Sci., 612;98-105, 1990.

5. Rund, D., Filon, D., Rachmilewitz, E.A. and Oppenheim, A. The relevance of mean corpuscular volume (MCV) of -thalassemia.bheterozygotes to prenatal diagnosis of  Annals of the N.Y. Acad. Sci., 612:514-517, 1990.

6. Rund, D., Filon, D., Dowling, C., Carol, E., Rachmilewitz, E. A., Kazazian, H.H. Jr., Oppenheim, A. Diversity of -thalassemia in Israeli Jewish ethnic groups. In:bmolecular lesions causing  Genetic Diversity Among Jews: Diseases and Markers at the DNA Level. B. Bonne-Tamir, A. Adam, eds., Oxford University Press, NY, 1991, pp228-236.

7. Filon, D., Rund, D., Rachmilewitz, E.A., Oppenheim, A.: Advances in the prenatal diagnosis of beta thalassemia in Israel. In: Genetic Diversity Among Jews; Diseases and Markers at the DNA Level. B. Bonne-Tamir, A. Adam, eds., Oxford University Press, NY, 1991, pp. 358-364.

8. Rund, D., Fibach, E., Polliack, A.  Functional asssment of multidrug resistance in hematologic malignancies. In, Advances in Blood Disorders, R. Pieters, ed., Amsterdam: Harwood Academic Publishers,1996, p.275-280.

9. Rund, D., Oron, V., Filon, V., -globin mutations and rearrangements in Israel: PCR-basedaOppenheim, A.  analysis reveals ethnic diversity. Annals of NY Acad Sci., 850:426-428, 1998.

10. Rund, D., Azar, I., Shperling, O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to resistant disease. Advances in Experimental Medicine and Biology: Drug Resistance in Leukemia and Lymphoma III, Kaspars, G. J. L. and R. Pieters,            eds. New York: Kluwer Press, 1999, p. 71-76. Proceedings of the Third International Conference on Drug Resistance in Leukemia and Lymphoma, Amsterdam, the Netherlands, March 4-7, 1998.

11. Rund, D. Thalassemia intermedia: Clinical aspects and treatment. Proceedings of Thalasssemia and Sickle Cell Anemia in the Mediterranean. European Genetics Foundation, Sestri Levante, Italy, Nov. 20-22, 1999.

12. Rund, D., Oron-Karni, V., Filon, D., -thalassemia: unusual geographic prevalenceaRachmilewitz, E. A., Oppenheim, A.  and genotypic diversity. Blood 94 (Suppl 1):50-51, 1999.

Chapters in Books, Submitted

1. Rund, D., Rachmilewitz, E.A. Thalassemia: the disease and its distribution among the Jews of Israel. In, Desnick, R., ed. Advances in Jewish Genetic Diseases. New York: Oxford University Press, submitted.

2. Rund, D., Rund D.A., Filon, D. Thalassemia mutations worldwide and methods of their detection. In: Thalassemia: Diagnosis and Treatment, Maggio, Aurelio, editor. Submitted, 2002.

Selected Abstracts Published/ Presented at Meetings

1. Rund, D., Dobkin, C. and Bank, A. - globin genes.bAmplification and expression of transfected human  Blood 66 (Suppl): 74a, 1985. Presented at the 27th Annual Meeting of the American Society of Hematology, Washington, DC, December, 1985. (Poster)

 2. Rund, D., Dobkin, C., and Bank, A. -globin genes.bAppropriate expression of amplified human  Clin. Res., 34: 469A, 1986. Presented at the May 1986 meeting of the American Federation of Clinical Research, Washington, D.C. (Oral Presentation)

3. Rund, D. Appropriate expression of -globin genes. Presented at the Society for the Study of Blood,bamplified human  May 20, 1986. (Oral Presentation)

4. Filon, D., Rund, D., Oppenheim, A. and Rachmilewitz, E. A. DNA based prenatal diagnosis of thalassemia: the Jerusalem Experience. Presented at : Xth Congress of the International Society of Haematology (European & African Division), Jerusalem, Israel, September,1989. (Poster)

5. Rund, D., Filon, D., Rachmilewitz, E.A., Kazazian, H.H. Jr. and Oppenheim, A. novel mutations: their prevalence and -thalasssemia.bfrequency among Kurdish Jews with

Presented at: Xth Congress of the International Society of Haematology (European & African Division), Jerusalem, Israel, September, 1989. (Poster)

6. Rund, D., Kazazian, H.H. Jr. and Oppenheim, A. RNA analysis of a novel polyadenylation signal mutation. Presented at : Xth Congress of the International Society of Haematology (European & African Division), Jerusalem, Israel, September, 1989. (Poster)

7. Rund, D., Filon, D., Rachmilewitz, E. A., Cohen, T., Dowling, C., Kazazian, H.H. Jr. and Oppenheim, A. Molecular -thalassemia in Kurdish Jews: Novel mutations and expressionbanalysis of  studies. Blood 74 (Suppl.):220a, 1989. Presented at: 31st Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December, 1989. (Poster)

 8. Oppenheim, A., Rund, D., Cohen, T., Filon, D., Dowling, C., Barak, I., Rachmilewitz, E.A., Kazazian, H.H. Jr. Evolution of a -thalassemia in the Jews of Kurdistan.bgenetic disease in an ethnic isolate:  Presented at: American Society of Human Genetics 41st Annual Meeting, Cincinnati, Ohio, October, 1990. (Poster)

9. Rund, D., Dowling, C., Rachmilewitz, -globinbE.A., Kazazian, H.H. Jr., Oppenheim, A. Novel mutations in the  polyadenylylation signal reveal extended transcripts and new RNA polyadenylylation sites. Presented at: 15th International Congress of Biochemistry, Jerusalem, Israel, August, 1991. (Poster)

10.Filon, D., Rund, D., Shaag, A., Dowling, C., Kazazian, H.H. Jr., Rachmilewitz, E.A. and Oppenheim, A. Molecular analysis of -thalassemia in Israeli ethnic groups and its applications to prenatalb diagnosis. Presented at: 15th International Congress of Biochemistry, Jerusalem, Israel, August, 1991. (Poster)

11. Rund, D., Vuilliamy, T., Rachmilewitz, E.A., Gold, A., Luzzatto, L. Episodic CD8 + lymphocytosis evolves into fulminant T cell leukemia-lymphoma: Retrospective diagnosis using T cell receptor rearrangements. Blood 79 (Suppl.):470a, 1991.

12. Oron, V., Filon, D., Fearson, C., Kazazian, H.H. Jr., Oppenheim, A., Rund, D-thalassemiab. Two novel  mutations in Ashkenazi Jews. Blood 80 (Suppl.):5a, 1992. Presented at: 34th Annual Meeting of the American Society of Hematology, Anaheim, California, December, 1992. (Poster)

13. Rund, D., Filon, D., Oron, V., Rachmilewitz, E.A., Kazazian, H.H. Jr. Oppenheim, A. Molecular analysis of -thalassemia intermedia in Israel reveals variable correlation between genotypeb and phenotype and unknown gene interactions. Blood 80 (Suppl.): 5a, 1992. Presented at: 34th Annual Meeting of the American Society of Hematology, Anaheim, California, December, 1992. (Poster)

14. Gillis, S., Dann, E. J., Rachmilewitz, E.A. and Rund, D. Selected discharge of patients with acute myeloid leukemia (AML) during chemotherapy-induced neutopenia. Blood 82 (Suppl.): 539a, 1993.

15. Rund, D., Gillis, S., Ruchlemer, R., Sinberger, A. and Dann, E,J. Sequential assessment of multidrug resistance (MDR1) activity in acute myeloid leukemia (AML) using rhodamine 123 staining: detection of chemoresistant subpopulations and prediction of clinical outcome. Blood 82 (Suppl.): 547a, 1993.

16. Rund, D., Sinberger, A. and Polliack, A. Variability of multidrug resistance gene (MDR) activity in chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphomas (NHL), determined by a functional analysis using rhodamine 123 staining. Blood 82 (Suppl.):576a, 1993.

Presented at: 35th Annual Meeting of the American Society of Hematology, St. Louis, Missouri, December, 1993. (Poster)

17. Rund, D. Serial Assessment of MDR1 activity in acute myeloid leukemia (AML) shows in vivo selection of chemoresistant populations and both MDR1-mediated and non-MDR1-mediated drug resistance. Journal of Cell. Biochem. 18D (Suppl.), 108, 1994. Presented at: Keystone Symposium on Cell Biological            Mechanisms of Drug Resistance, Tamarron, Colorado, March, 1994.  (Poster)

18. Rund, D., Sinberger, A. and Polliack, A. Variability of multidrug resistance gene (MDR) activity in chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphomas (NHL), determined by a functional analysis using rhodamine 123 staining. Br. J. Haematology 86 (Suppl1);76, 1994. European Society of Hematology Annual Meeting, 1994 (Poster)

19. Rund, D., Fibach, E., Polliack, A. High frequency and stability of Mulitidrug resistance gene (MDR1) phenotype in chronic lymphatic leukemia (CLL) versus B-cell and high grade non-Hodgkins lymphomas (NHL): Functional assessment using rhodamine 123. Blood 84 (Suppl) 451a, 1994. Presented at the 36th annual meeting of the American Society of Hematology, Nashville, Tenn, December 2-6, 1994. (Poster)

20. Rund, D., Fibach, E., Polliack, A. Functional assessment of Multidrug Resistance Gene 1 in hematologic malignancies using rhodamine 123. Leukemia 9:546a, 1995. Presented at the 2nd International Symposium on Drug Resistance in Leukemia and Lymphoma, Amsterdam, March 6-8, 1995. (Poster)

21. Caspi, O., Krichevsky, S., Rund, D., Abeliovich, D., Zelig, O., Polliack, A., Paltiel, O., Rachmilewitz, E.A., Ben-Yehuda, D. Molecular analysis of secondary leukemias: mutator phenotype            as the cause of different p53 mutations in multiple malignancies in the same individual. Blood 86 (Suppl);167a, 1995. Presented at the 37th annual meeting of the American Society of Hematology, Seattle, Washington, December 1-5, 1995. (Poster)

22. Rund, D., Dagan, M., Schoenlein, P., Gottesman, M., Oppenheim, A. SV40/MDR1 Vector for gene delivery into human hematopoietic cells. Blood 87 (Suppl);237a, 1995. Presented at the 37th annual meeting of the American Society of Hematology, Seattle, Washington, December 1-5, 1995.

23. Steiner, H., Polliack A., Fibach, E., Rund, D. Are there gender differences in multidrug resistance gene (MDR1) expression in chronic lymphocytic leukemia? Blood 88 (Suppl 1) 241a, 1996. Presented at American Society of Hematology 38th annual meeting, Orlando, Florida, Dec 5-9, 1996.

24. Oron-Karni, V., Filon, D., Oppenheim, A., Rund, D. Three novel -thalassemia in various Israeli ethnic groups.amutations causing  Blood 88 (Suppl 1) 153a, 1996. Presented at American Society of Hematology 38th annual meeting, Orlando, Florida, Dec 5-9, 1996. (Poster)

25. Rund, D., Steiner, H., Fibach, E., Polliack, A. Multidrug resistance gene (MDR1) activity in B-cell chronic lymphocytic leukemia: possible gender and stage effects. Presented at the VII International Workshop on CLL, Crete, 2-4 May, 1997 (Poster)